Financials data is unavailable for this security.
View more
Year on year Chengdu Easton Biopharmaceuticals Co Ltd 's revenues fell -4.56% from 1.17bn to 1.12bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 246.52m to 226.57m, a -8.09% decrease.
| Gross margin | 76.27% |
|---|---|
| Net profit margin | 19.62% |
| Operating margin | 20.84% |
| Return on assets | 7.32% |
|---|---|
| Return on equity | 9.33% |
| Return on investment | 9.12% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Chengdu Easton Biopharmaceuticals Co Ltd fell by 54.32m. However, the company earned 275.25m from its operations for a Cash Flow Margin of 24.64%. In addition the company generated 80.67m cash from financing while 410.17m was spent on investing.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 15.11 |
|---|---|
| Tangible book value per share | 14.56 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.66 |
|---|---|
| Quick ratio | 2.42 |
| Total debt/total equity | 0.112 |
|---|---|
| Total debt/total capital | 0.1007 |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share increased 3.57% while earnings per share excluding extraordinary items fell by -7.93%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.83% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 28.57% |
| EPS growth(5 years) | 4.73 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -0.6411 |
More ▼
